An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
Conditions: Non-metastatic Castration-resistant Prostate Cancer; Metastatic Hormone-sensitive Prostate Cancer Interventions: Drug: Darolutamide (Nubeqa, BAY1841788) Sponsors: Bayer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Hormones | Learning | Prostate Cancer | Research | Study | Universities & Medical Training